IL17A and psoriasis: Secukinumab is a fully human anti-IL-17A immunoglobulin G 1κ (IgG1κ) monoclonal antibody that selectively binds to and neutralizes IL-17A to alleviate diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis (66).